Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn
AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th
The UK’s VPAS – a deal that began on 1st January 2019 and which is due to end on 31st December 2023 – is worth around £7 billion.
Personalised and precision health is a firmly established concept in the development of new prescription medicines, but not so much in the consumer health category.
Editor's Picks
